Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study

International Journal of Clinical Practice

Volumn 63, Issue 4, 2009, Pages 547-559

  Farnier, M ^a   Averna, M ^b   Missault, L ^c   Vaverkova, H ^d   Viigimaa, M ^e   Massaad, R ^f   Vandormael, K ^f   Johnson Levonas, A O ^g   Brudi, P ^h  

^a Point Medical   (France)

^b UNIVERSITY OF PALERMO   (Italy)

^c General Hospital St Jan   (Belgium)

^d UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^e TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^f Merck Sharp and Dohme   (Belgium)

^g MERCK RESEARCH LABORATORIES   (United States)

^h Merck/Schering Plough   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLANGITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPATHY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHABDOMYOLYSIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; AZETIDINES; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRIMIDINES; RISK FACTORS; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 62549118503     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02022.x     Document Type: Article

References (31)

1. La Rosa JC. Low-density lipoprotein cholesterol reduction: the end is more important than the means. Am J Cardiol 2007 100 : 240 2.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
3. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007 28 : 2375 414.
4. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 110 : 227 39.
5. Jones PH. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options. Am Heart J 2004 148 (1 Suppl S9 13.
6. AstraZeneca Pharmaceuticals LP. Crestor (Rosuvastatin). Wilmington, DE : AstraZeneca Pharmaceuticals LP, 2008 [prescriber information].
7. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003 92 : 152 60.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
9. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 78.
10. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 350 : 1495 504.
11. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352 : 1425 35.
12. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005 294 : 2437 45.
13. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006 48 : 438 45.
14. Smith SC Jr., Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006 113 : 2363 72.
15. Davidson MH, Maki KC, Pearson TA et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005 96 : 556 63.
16. Laforest L, Moulin P, Souchet T et al. Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy. Atherosclerosis 2008 199 : 368 77.
17. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001 111 : 185 91.
18. Knopp RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003 24 : 729 41.
19. Bays HE, Ose L, Fraser N et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004 26 : 1758 73.
20. Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002 40 : 2125 34.
21. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004 79 : 620 9.
22. MERCK/Schering-Plough Pharmaceuticals. Vytorin (Ezetimibe/Simvastatin) Tablet. North Wales, PA : MERCK/Schering-Plough Pharmaceuticals, 2008 [prescriber information].
23. MSD-SP Limited. Inegy (Ezetimibe/Simvastatin). Hoddesdon, Hertfordshire, UK : MSD-SP Limited, 2008 [package leaflet].
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18 : 499 502.
25. Barrios V, Amabile N, Paganelli F et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005 59 : 1377 86.
26. Constance C, Westphal S, Chung N et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2007 9 : 575 84.
27. Reckless JP, Henry P, Pomykaj T et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract 2008 62 : 539 54.
28. Roeters van Lennep HW, Liem AH, Dunselman PH et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin 2008 24 : 685 94.
29. Kindermann M, Adam O, Werner N, Böhm M. Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007. FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO. Clin Res Cardiol 2007 96 : 767 86. Epub 2007 Oct 25.
30. Catapano AL, Davidson MH, Ballantyne CM et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006 22 : 2041 53.
31. Pisciotta L, Fasano T, Bellocchio A et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 2007 194 : e116 22.